Ann: Botanix Presents at Fall Clinical Dermatology Conference, page-117

It really was a stunning article highlighting where this smart money is heading. For them like other investments it is risk reward related and they know a lot of money has hone into oncology and rheumatoid issues. The simple less risk dermatological programs with high end results start to look very tempting. Are they ahead of the game these funds who do know it all takes time or are they looking at multiple and multiple bags and return on their investments?

I am hoping the supply and demand counterbalance starts tilting with new announcements.